Calamos Advisors LLC Raises Stake in Humana Inc. (NYSE:HUM)

Calamos Advisors LLC increased its stake in shares of Humana Inc. (NYSE:HUM) by 8.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 76,948 shares of the insurance provider’s stock after purchasing an additional 6,207 shares during the period. Calamos Advisors LLC’s holdings in Humana were worth $35,228,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in HUM. Rakuten Securities Inc. purchased a new stake in Humana during the 4th quarter worth about $25,000. Gradient Investments LLC increased its stake in Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 40 shares during the last quarter. Sunbelt Securities Inc. bought a new position in Humana in the 1st quarter worth about $28,000. Householder Group Estate & Retirement Specialist LLC bought a new position in Humana in the 3rd quarter worth about $39,000. Finally, Nvwm LLC increased its stake in Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after acquiring an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HUM. Oppenheimer restated an “outperform” rating and issued a $630.00 target price on shares of Humana in a research note on Wednesday, January 17th. The Goldman Sachs Group decreased their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Mizuho decreased their target price on Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, January 26th. TD Cowen decreased their target price on Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $391.00 target price on shares of Humana in a research note on Wednesday, April 10th. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $465.42.

Humana Trading Up 0.4 %

HUM traded up $1.37 on Thursday, hitting $324.83. 1,475,316 shares of the company were exchanged, compared to its average volume of 2,008,112. Humana Inc. has a 12 month low of $299.23 and a 12 month high of $541.21. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The firm has a fifty day simple moving average of $344.41 and a two-hundred day simple moving average of $425.71. The stock has a market capitalization of $39.19 billion, a PE ratio of 16.47, a price-to-earnings-growth ratio of 1.86 and a beta of 0.45.

Humana (NYSE:HUM) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $26.46 billion during the quarter, compared to analysts’ expectations of $25.47 billion. During the same quarter last year, the business posted $1.62 EPS. The company’s quarterly revenue was up 17.9% compared to the same quarter last year. Sell-side analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.09%. Humana’s dividend payout ratio (DPR) is currently 17.86%.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.